Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca

{
  "signal_id": "14c55f34-eac2-f353-fa34-85dc186dacad",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-08T08:08:00+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/08/3357362/28124/en/assessment-of-the-rheumatoid-arthritis-market-2026-2036-featuring-rise-therapeutics-taiho-pharmaceutical-abbvie-eli-lilly-incyte-and-astrazeneca.html",
    "title": "Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca",
    "excerpt": "Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. Rheumatoid Arthritis Market Forecast to Reach New Growth Milestones Through 2036, Driven by Targeted Therapies and Expanding Patient Demand The report provides a comprehensive analysis of the rheumatoid arthritis market across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The report examines historical and forecast epidemiology, treatment practices, marketed products, emerging therapies, competitive dynamics, market access, reimbursement, and commercial opportunities from 2022 through 2036. Rheumatoid Arthritis Market Size and Forecast The rheumatoid arthritis therapeutics market is expected to expand as prevalence increases, diagnostic capabilities improve, and treatment strategies continue to shift toward early intervention, sustained remission, and prevention of structural joint damage. Aging populations, long-term healthcare utilization, and the introduction of targeted biologic and oral therapies are also supporting market growth. Nearly one in four Americans, or approximately 60 million people, is affected by arthritis. Rheumatoid arthritis accounts for a substantial share of chronic inflammatory disease burden, with persistent...",
    "product": "AZD1163",
    "summary": "AstraZeneca is developing AZD1163, a rheumatoid arthritis drug candidate which has advanced to Phase II clinical trials.",
    "planning": true,
    "image_url": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
    "confidence": 0.9,
    "product_data": {
      "name": "AZD1163",
      "full_text": "AZD1163",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-08T08:08:00Z",
    "article_sentence": "According to AstraZeneca's fiscal year 2025 clinical trial appendix, AZD1163 advanced to Phase II, while AZD6912 remained in Phase I."
  }
}

curl https://signals.autobound.ai/v1/signals/14c55f34-eac2-f353-fa34-85dc186dacad \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'